Compare BridgeBio Pharma Inc (BBIO) vs Herbalife Nutrition Ltd (HLF) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

HLF trades at $11.52, down 6.72% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company reported Q2 2026 net sales of $1.3 billion, up 5.4% year-over-year, but missed EPS estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels remain concerns. Recent news includes a planned CFO transition in December 2026 and inclusion in TIME's America's Best Companies list.

The outlook is cautious due to inconsistent earnings performance and a highly leveraged balance sheet, but low valuation metrics and analyst consensus leaning buy (53.84%) suggest potential upside if operational improvements and debt reduction continue. Key risks include execution challenges, competitive pressures, and sensitivity to macroeconomic conditions.